Luye Pharma Group Ltd. (2186.HK)
Develops and sells cancer drugs, diabetes medications, and psychiatric treatments across China and globally.
2.10+0.00%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-46.8%
The outlook
Luye Pharma trades near the low end of its 52-week range at 2.1 HKD, with a mixed price trend relative to its moving averages. Analyst sentiment leans bearish overall, though the average price target sits roughly 68% above the current level. The stock's trailing P/E of 15.0 reflects modest valuation relative to earnings.
What’s behind the score
Price trendMixed vs its moving averages
52-week range13% of the way from its 52-week low to high
Price targetAvg target +68% vs current price
Analyst price target
~12-month · 2 analysts3.53average target+68.1% vs now
Now 2.10
Low 2.72High 4.34
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$8.39B
52-wk high
4.49
52-wk low
1.73
50-day avg
2.04
200-day avg
2.63
Trailing P/E
15.0